Coverage

2-May-2024	Kazia reports successful stage 1 completion of the EVT801 Phase 1 clinical trial in advanced cancer patients

11-Feb-2024	Professor takes big step in fighting cancer which claimed his daughter

23-Dec-2023	Parents of kids with DIPG say funding for trial urgently needed

23-Nov-2023	Kazia provides overview of Paxalisib related presentations from the Society of Neuro-Oncology 2023 Annual Meeting

1-May-2023	Kazia Therapeutics appoints Dr John Friend as new CEO

4-Apr-2023	Kazia Therapeutics to present new pipeline molecule data at AACR 2023

6-Mar-2023	Kazia Therapeutics forms clinical collaboration for Australian Phase 2 study of paxalisib, targeting childhood cancers

28-Feb-2023	Kazia Therapeutics raises A$7 million to fund R&D pipeline

6-Feb-2023	After a successful $4.5 million cap raise and with cancer trial results to come, Kazia is optimistic for 2023

31-Jan-2023	ASX rose 6.2% in January: Aus shares closed the day 0.07% lower

31-Jan-2023	High cost of living causes a fall in retail sales: ASX up 0.22% at noon

17-Jan-2023	Kazia Therapeutics CEO talks $4.5 million capital raise

16-Jan-2023	Kazia Therapeutics raising $4.5 million in placement; launches SPP

20-Dec-2022	Kazia Therapeutics exploring use of lead asset in other cancers: Edison Investment Research

14-Dec-2022	Kazia Therapeutics files patent as it continues to work with QIMT on cancer research

9-Dec-2022	SMH: ‘Waiting for your child to die is not an option’

8-Dec-2022	Kazia Therapeutics’ upcoming top-line data for EVT801 expected to be a share price catalyst: Edison Investment Research

5-Dec-2022	Kazia Therapeutics talks positive pre-clinical data for EVT801

1-Dec-2022	Almost all sectors higher: Aus shares close up 1%

1-Dec-2022	ASX opens to 7-month high after Powells positive news: Aus shares up 0.8%

30-Nov-2022	Kazia Therapeutics welcomes publication of positive pre-clinical data for EVT801 in peer-reviewed cancer research journal

1-Nov-2022	ASX increases slightly ahead of today's interest rate rise: Aus shares 0.3% higher at noon

28-Oct-2022	US tech earnings weighing down Aus tech sector: ASX falls 0.62% at noon

28-Oct-2022	Stocks of the Hour: Kazia Therapeutics, Green Technology Metals, Winsome Resources

28-Oct-2022	Kazia Therapeutics’ (ASX:KZA) paxalisib shows positive signals against preclinical melanoma models

5-Oct-2022	Kazia Therapeutics takes Phase 2 study of paxalisib international; opens two sites in Australia

27-Sep-2022	Stockhead Health and Biotech Investment Guide

8-Aug-2022	Stocks of the Hour: Kazia Therapeutics, Mesoblast, BHP &Oz Minerals

8-Aug-2022	ASX edges lower in morning trading, reporting season kicks off: Aus shares down 0.2% at noon

8-Aug-2022	Kazia Therapeutics gives progress report on GBM AGILE pivotal study for glioblastoma

7-Aug-2022	Kazia Therapeutics' promising data on treatment targeting brain metastases to be presented at conference

11-Jul-2022	Kazia Therapeutics forms new Scientific Advisory Board with world-leading experts in brain cancer

7-Jul-2022	Tech snaps 4-day winning streak, Iron ore miners rebound: ASX closes 0.8% higher

7-Jul-2022	Australia trade surplus hits record high, Chalice Mining soars on discovery: ASX up 0.2% at noon

7-Jul-2022	Stocks of the Hour: Elsight, Kazia Therapeutics, Chalice Mining

6-Jul-2022	Kazia Therapeutics gains US FDA Rare Paediatric Disease Designation for paxalisib in rare form of childhood brain cancer

30-Jun-2022	Kazia Therapeutics continues to make good progress on cancer treatment assets

17-Jun-2022	Kazia Therapeutics secures orphan drug designation for treatment of AT/RT tumours with paxalisib

14-Jun-2022	Stocks of the Hour: Kazia Therapeutics, Westgold Resources &Lake Resources

13-Jun-2022	Kazia Therapeutics welcomes presentation of positive paxalisib data at international symposium

8-Jun-2022	Kazia onto next chapter in Phase 2 brain metastases trial

7-Jun-2022	Kazia Therapeutics’ Phase 2 paxalisib study moves to expansion stage in breast cancer brain metastases cohort

31-May-2022	Kazia Therapeutics’ paxalisib now the subject of multi-drug platform study at the University Hospital, Zurich

11-May-2022	Sector Watch: Healthcare - M&Afever on the cards?

11-May-2022	Nasdaq jumps as Dow falls, Immutep, Antisense, Pushpay, AGL, Star on watch: ASX poised to open lower

5-May-2022	Kazia Therapeutics and its flagship asset have made significant progress against brain cancers: Pitt Street Research

2-May-2022	Kazia Therapeutics wraps up a busy quarter presenting paxalisib data at the AACR annual meeting

25-Apr-2022	Kazia Therapeutics establishes ‘at the market’ equity program

21-Apr-2022	Kazia Therapeutics completes Phase 2 study of glioblastoma drug Paxalisib; data to follow at conference

8-Apr-2022	Kazia Therapeutics encouraged by “promising data” on its cancer pipeline presented at AACR meeting in New Orleans

28-Feb-2022	Kazia Therapeutics initiates Phase II study of paxalisib for newly diagnosed and recurrent glioblastoma

24-Feb-2022	Kazia Therapeutics delivers on plans with two promising assets in human trials

12-Dec-2021	Kazia Therapeutics appoints US-based CFO to assist global market expansion

9-Dec-2021	Kazia Therapeutics' clinical paxalisib data maintains Speculative Buy rating from Bell Potter

3-Dec-2021	Kazia Therapeutics (ASX:KZA) announces positive results for brain cancer drug

3-Dec-2021	ASX up, Berkshire billionaire gives his views on crypto and will BHP benefit from rising iron ore prices?

2-Dec-2021	Kazia Therapeutics releases positive final data from Phase 2 trial of glioblastoma treatment paxalisib, shares up

29-Nov-2021	Kazia Therapeutics expands further in North America with Toronto glioblastoma study

15-Nov-2021	Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO

10-Nov-2021	Kazia Therapeutics welcomes start of PNOC study in childhood brain cancer, first patient enrolled

7-Nov-2021	Kazia Therapeutics marks big step forward as first patient enrols in EVT801 cancer therapy trial

4-Nov-2021	Kazia Therapeutics enrols first patient to phase I clinical trial of EVT801 cancer therapy

28-Oct-2021	Kazia Therapeutics gets boost with ‘buy’ call from Maxim Group and valuation upgrade from Edison

14-Oct-2021	Kazia Therapeutics’ paxalisib program data garners increased target share price of A$2.83 from Edison

14-Sep-2021	Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference

2-Sep-2021	Kazia Therapeutics receives full regulatory approval for EVT801 phase 1 study

9-Dec-2020	Kazia Therapeutics (ASX:KZA) see promising data from Phase 1 ovarian cancer trial

27-Apr-2020	Kazia Therapeutics (ASX:KZA) glioblastoma Phase II trial results

Subscribe to Email Alerts

Follow Us

Copyright © Kazia Therapeutics Limited

Design byspatialdesign Site by